➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Dow
Colorcon
Baxter
Moodys

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Claims for Patent: 4,174,389

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,174,389
Title: Ophthalmic use of collagenase
Abstract:A method for the selective lysis of collagen fibrils located in the ocular region of a mammal comprising injecting into said ocular region an effective amount of a pharmacologically suitable solution comprising collagenase; and contacting said fibrils with said solution for a period of time sufficient to lyse said fibrils.
Inventor(s): Cope; Louise A. (Houston, TX)
Assignee:
Application Number:05/796,807
Patent Claims:1. A method for the selective lysis of collagen fibrils located in the vitreous of the ocular region of a mammal comprising:

injecting intravitreally a small but effective amount of a pharmacologically suitable solution comprising a concentrated amount of collagenase;

contacting said fibrils with said solution;

flushing the intravitreal region by injecting an effective amount of an inactivator of collagenase solution; and

removing said collagenase solution from said intravitreal region before said solution damages other ocular structures not intended to be affected thereby.

2. The method of claim 1 wherein said steps of injecting an inactivator of collagenase solution and removing said collagenase solution are performed substantially simultaneously.

3. A method for the selective lysis of collagen fibrils located in the vitreous of the ocular region of a mammal comprising:

preparing a pharmacologically suitable solution comprising collagenase produced from the bacterium Clostridium histolyticum by addmixing a concentrated amount of said collagenase with a solution having a pH of about 7.40 and containing a sufficient amount of calcium ions to activate said collagenase;

injecting intravitreally a small but effective amount of said pharmacologically suitable solution comprising a concentrated amount of collagenase;

flushing the intravitreal region by injecting an effective amount of an inactivator of collagenase solution; and

removing said collagenase from said intravitreal region before said solution damages other ocular structures not intended to be affected thereby.

4. The method of claim 3 wherein said steps of injecting an inactivator of collagenase solution and removing said collagenase solution are performed substantially simultaneously.

5. A method for the selective lysis of collagen fibrils located in the anterior chamber of the ocular region of a mammal comprising:

injecting into said anterior chamber a small but effective amount of a pharmacologically suitable solution comprising a concentrated amount of collagenase;

contacting said fibrils with said solution; and

removing said collagenase solution from said anterior chamber before said solution damages other ocular structures not intended to be affected thereby.

6. The method of claim 5 wherein said collagenase is naturally removed from said anterior chamber.

Details for Patent 4,174,389

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial 2039-03-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Baxter
Harvard Business School
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.